India Adds Stronger Safety Warnings to Doxycycline and Carbimazole Packages
India's drug regulator has mandated stronger safety warnings for doxycycline and carbimazole after a national review of adverse reaction reports. Doxycycline packages will now list potential mental health side effects such as anxiety and dizziness, while carbimazole will warn of a rare blood disorder.
Two widely used medicines—doxycycline and carbimazole—will soon carry stronger safety warnings in India following a national review of adverse drug reaction reports. The Central Drugs Standard Control Organisation (CDSCO) and the Drugs Controller General of India (DCGI) have directed all State and Union territory licensing authorities to ensure manufacturers update prescribing information and package inserts for both medicines and report compliance.
For doxycycline, an antibiotic commonly prescribed for respiratory infections, acne, sexually transmitted infections, urinary tract infections, and vector-borne diseases, the updated labels will explicitly list central nervous system side effects including restlessness, anxiety, irritability, nervousness, and dizziness. While gastrointestinal discomfort and photosensitivity were already recognized side effects, the latest directive formally adds neuropsychiatric symptoms to its safety profile. The decision follows an assessment by the Pharmacovigilance Programme of India (PvPI), which reviewed adverse reaction reports and individual case safety data. The issue was examined by the Signal Review Panel in March 2025 and subsequently endorsed by the Subject Expert Committee (SEC) on antimicrobial and antiparasitic drugs in January 2026.
Carbimazole, prescribed for hyperthyroidism including Graves' disease, will now prominently warn about agranulocytosis, a rare but potentially life-threatening condition marked by a sharp decline in white blood cells. This can leave patients highly vulnerable to severe infections, with early warning signs including fever, sore throat, and unexplained infections. The recommendation originated from the 26th Signal Review Panel meeting and was later reviewed by the SEC on endocrinology and metabolism before regulatory approval.
Dr. Rommel Tickoo, Director of Internal Medicine at Max Hospital Saket, said the move reflects a maturing pharmacovigilance system. He noted that while both medicines remain safe and effective when used appropriately, clearer warnings help doctors and patients recognize rare but important side effects early. For carbimazole, prompt medical attention for symptoms like fever or sore throat can be life-saving. Such regulatory steps strengthen patient safety without creating unnecessary alarm.
The updated package inserts will provide patients with clearer information about potential risks, while clinicians are advised to counsel patients on warning symptoms and to monitor treatment appropriately.